Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Uveal Melanoma 1Uterine Cervical Neoplasms 1Solid Tumors, Adult 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 5Pemetrexed 4pembrolizumab 3osimertinib 3entinostat 3selpercatinib 2durvalumab 2camrelizumab 2Erlotinib Hydrochloride 2sotorasib 1repotrectinib 1pralsetinib 1patritumab 1napabucasin 1exemestane 1cobimetinib 1ceralasertib 1capmatinib 1alectinib 1aflutinib 1Toll-Like Receptor 1 1TNFSF10 protein, human 1Patient Reported Outcome Measures 1Paclitaxel 1Injections 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bronchial Neoplasms × Toll-Like Receptor 1 × Clear all
NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡